Clinical TrialThe long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Under a Creative Commons license
open access
Graphical abstract
Keywords
atypical hemolytic uremic syndrome
complement
eculizumab
hemolytic uremic syndrome
ravulizumab
thrombotic microangiopathy
Cited by (0)
© 2020 International Society of Nephrology. Published by Elsevier Inc.